PharmaShots Weekly Snapshots (April 22 – April 26, 2024)

Share this

PharmaShots Weekly Snapshots (April 22 – April 26, 2024)

This week PharmaShots’ news was all about the updates on Regulatory, Clinical Trials, Pharma, Animal Health & MedTech.

Check out our full report below: 


Health Canada Accepts Filling and Priority Review of Acadia’s TROFINETIDE for Rett Syndrome

Read More: Health Canada                                                                                            

US FDA Granted Fast Track Designation to Medicure’s MC-1 for PNPO deficiency

Read More: US FDA                                                                                                        

EMA Granted Extended Approval to Astellas’ XTANDI (Enzalutamide) for Recurrent Early Prostate Cancer Treatment

Read More: EMA                                                                                                             

CSL Vifor and Travere Therapeutics’ FILSPARI (sparsentan) Received European Commission Approval Against IgA Nephropathy

Read More: CSL

Ascendis Pharma Receives MHRA Approval for YORVIPATH (Palopegteriparatide) Against Chronic Hypoparathyroidism in Great Britain

Read More: Ascendis

Blue Arbor’s RESTORE Neuromuscular Interface System Receives FDA Breakthrough Device Designation & TAP Enrolment

Read More: Blue Arbor 

Medivir’s MIV-711 Receives FDA ODD and RPDD for Legg-Calvé-Perthes Disease

Read More: Medivir 

US FDA Grants Fast Track Designation to Compass Therapeutics’ CTX-009 with Paclitaxel for Previously Treated Metastatic or Locally Advanced Biliary Tract Tumors.

Read More: US FDA   


Aurigene and Vipergen Enter into a Strategic Collaboration to Offer DEL Screening and Integrated Drug Discovery Services

Read More: Aurigene and Vipergen 

Ipsen Enters into an Option Agreement with Skyhawk Therapeutics for Two RNA Targeting Small Molecules in Rare Neurological Diseases

Read More: Ipsen  

Ochre Bio and Boehringer Ingelheim Enter into a Collaboration to Develop and Commercialize Novel Regenerative Treatments for Advanced Liver Disease

Read More: Ochre Bio and Boehringer    

Vertex and Treefrog Therapeutics Sign a Licensing Agreement & Collaborate to Enhance Production of Vertex’s Cell Therapies for Type-I Diabetes

Read More: Vertex and Treefrog  

Angle Enters into a Supply Agreement with AstraZeneca to use DDR Assay in Pharmaceutical R&D

Read More: Angle  

MFDS Korea Approves Onconic Therapeutics’ JAQBO (Zastaprazan citrate) for Treatment of Gastroesophageal Reflux Disease (GERD) in adults

Read More: MFDS Korea  

Regeneron and Mammoth Collaborate for CRISPR Gene Editing Therapies Against Multiple Diseases

Read More: Regeneron    


 Incyte to Acquire Escient Pharmaceuticals and its MRGPR Antagonist Assets

Read More: Incyte  

Labcorp to Acquire Invitae Under US Bankruptcy Code Section 363

Read More: Labcorp 


Cochlear's Osia System Gets FDA Clearance for Children Aged 5 Years and Above

Read More: Cochlear's

Immunovia Reports Positive Results of Next Generation Test from Model Development Study for Pancreatic Cancer Detection.

Read More: Immunovia


Hepion Pharmaceuticals Begins Wind-Down Activities in ASCEND-NASH P-IIb Study

Read More: Hepion 

GENETIKA+ and NeuroSense Commence Precision Medicine Collaboration with the Ongoing P-II Trial in Alzheimer’s Disease 

Read More: GENETIKA+  

Krystal Biotech doses First Patient with Inhaled KB707 in the P-I study for treating Locally Advanced or Metastatic Solid Tumors of the Lung

Read More: Krystal Biotech 

Sanofi’s Rilzabrutinib Meets Primary Endpoint of the LUNA-3 (P-III) Study for the Treatment of Immune Thrombocytopenia (ITP)

Read More: Sanofi

Neurocrine Biosciences Reports Positive Results from P-II study of NBI-1065845 in MDD

Read More: Neurocrine

CureVac collaborates with GSK to Initiate P-I/II study of Avian Influenza (H5N1)

Read More: CureVac

Atom Bioscience Initiates Enrolment in Global P-IIb/III Study of ABP-671 to Treat Chronic Gout in US

Read More:  Atom Bioscience

Vistagen Reports Positive Results from P-IIa Study of PH15 for Improvement of Psychomotor Impairment

Read More: Vistagen


Cresilon Teams Up with Covetrus, MWI Animal Health, and Patterson Veterinary Supply for VETIGEL (Haemostatic Gel)

Read More: Cresilon 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions